drugset
Drugs / JNJ-39758979
last change Jun 2018 re-read 2 minutes ago

JNJ-39758979

Small molecule

Developed for
asthma · rheumatoid arthritis · atopic eczema · urticaria
Investigated by
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Janssen Pharmaceutical K.K. · Janssen Research & Development, LLC

Trials 7 · a red edge is where a trial was stopped

today NCT01493882 · Ph 2 NCT01480388 · Ph 2 NCT01497119 · Ph 2 NCT01442545 · Ph 1 NCT01068223 · Ph 1 NCT01081821 · Ph 1 NCT00946569 · Ph 2
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT01442545 Aug → Dec 2011 rheumatoid arthritis Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 1 NCT01068223 Feb → May 2010 urticaria Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 1 NCT01081821 Feb → Dec 2010 — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 24 trials
Phase 2 NCT01493882 Mar 2012 → Jun 2015 asthma Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Withdrawn No outcome recorded
Phase 2 NCT01480388 Dec 2011 → Mar 2014 rheumatoid arthritis Janssen Research & Development, LLC Withdrawn No outcome recorded
Phase 2 NCT01497119 Oct 2011 → Feb 2012 atopic eczema Janssen Pharmaceutical K.K. Terminated No outcome recorded
Phase 2 NCT00946569 Aug 2009 → Sep 2010 asthma Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as JNJ 39758979 “JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily.” NCT01442545 ↗
8

“Single oral dose of JNJ-39758979 (either 50, 100, 300, 600mg) or Placebo” NCT01081821 ↗

“JNJ-39758979 is a potent and highly selective oral H4 R antagonist.” PMID 29682796 ↗ Jun 2018

NCT01068223 ↗

NCT01480388 ↗

NCT01493882 ↗

NCT00946569 ↗

NCT01497119 ↗

NCT01442545 ↗
Action Inhibit “JNJ-39758979 is a potent and highly selective oral H4 R antagonist.” PMID 29682796 ↗ Jun 2018
Modality Small molecule — CHEMBL3236549 ↗
Route Oral “Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks.” NCT00946569 ↗